Cargando…

An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells

Refractory T cell acute leukaemias that no longer respond to treatment would benefit from new modalities that target T cell-specific surface proteins. T cell associated surface proteins (the surfaceome) offer possible therapy targets to reduce tumour burden but also target the leukaemia-initiating c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Jain, Arvind, Milhas, Sabine, Williamson, Daniel J., Mysliwy, Justyna, Lodge, Adam, Thirlway, Jenny, Al Nakeeb, Majid, Miller, Ami, Rabbitts, Terry H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pergamon Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443841/ https://www.ncbi.nlm.nih.gov/pubmed/34062328 http://dx.doi.org/10.1016/j.leukres.2021.106626

Ejemplares similares

Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds
por: Canning, Peter, et al.
Publicado: (2021)

Intracellular Antibodies for Drug Discovery and as Drugs of the Future
por: Rabbitts, T. H.
Publicado: (2023)

A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2
por: Bery, Nicolas, et al.
Publicado: (2021)

Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
por: Tanaka, Tomoyuki, et al.
Publicado: (2021)

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
por: Kalim, Muhammad, et al.
Publicado: (2017)

Structural Deformation of MTX Induced by Nanodrug Conjugation Dictate Intracellular Drug Transport and Drug Efficacy
por: Park, Jun-Young, et al.
Publicado: (2021)

Noncoding RNAs Emerging as Drugs or Drug Targets: Their Chemical Modification, Bio-Conjugation and Intracellular Regulation
por: Wang, Jin, et al.
Publicado: (2022)

GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells
por: Sewing, Sabine, et al.
Publicado: (2018)

Formulation and Intracellular Trafficking of Lipid–Drug Conjugate Nanoparticles Containing a Hydrophilic Antitubercular Drug for Improved Intracellular Delivery to Human Macrophages
por: Pandit, Sayantan, et al.
Publicado: (2020)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

Intracellular Metabolism and Cytotoxicity of Transferrin‐Neocarzinostatin Conjugates of Differing Molar Ratios
por: Sasaki, Katsunori, et al.
Publicado: (1993)

Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.
por: Durrant, L. G., et al.
Publicado: (1987)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer
por: Yoon, Dennis J., et al.
Publicado: (2011)

Antibody–Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome–Disruptive Peptide
por: Knewtson, Kelsey E., et al.
Publicado: (2019)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
por: Ritchie, Michael, et al.
Publicado: (2013)

Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity
por: Christianson, Helena C., et al.
Publicado: (2017)

Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats
por: Miller, Ami, et al.
Publicado: (2020)

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates
por: Heater, Natalie K., et al.
Publicado: (2023)

Evaluation of Anti-Inflammatory Drug-Conjugated Silicon Quantum Dots: Their Cytotoxicity and Biological Effect
por: Hanada, Sanshiro, et al.
Publicado: (2013)

Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors
por: Lipovšek, Daša, et al.
Publicado: (2018)

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
por: Jain, Arvind, et al.
Publicado: (2017)

Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues
por: Gonda, Kohsuke, et al.
Publicado: (2020)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
por: Perrone, Emanuele, et al.
Publicado: (2020)

The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
por: Melvik, J. E., et al.
Publicado: (1992)

Near‐infrared‐induced drug release from antibody–drug double conjugates exerts a cytotoxic photo‐bystander effect
por: Takahashi, Kazuomi, et al.
Publicado: (2022)

Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells
por: Qi, Jianjun, et al.
Publicado: (2022)

Supermolecule—Drug Conjugates Based on Acid-Degradable Polyrotaxanes for pH-Dependent Intracellular Release of Doxorubicin
por: Tamura, Atsushi, et al.
Publicado: (2023)

Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
por: Frenzel, Anna, et al.
Publicado: (2011)

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
por: Aoyama, Michihiko, et al.
Publicado: (2021)

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
por: Li, Wen‐Qian, et al.
Publicado: (2021)

Development of a Cytotoxic Antibody–Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells
por: Rodak, Aleksandra, et al.
Publicado: (2023)

Cytotoxicity Enhancement in Breast Cancer Cells with Carbonate Apatite-Facilitated Intracellular Delivery of Anti-Cancer Drugs
por: Fatemian, Tahereh, et al.
Publicado: (2018)

Peptide-Drug Conjugates: A New Hope for Cancer Management
por: Chavda, Vivek P., et al.
Publicado: (2022)

RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells
por: Lee, Sang Gon, et al.
Publicado: (2018)

Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis
por: Takahashi, Jun-ichiro, et al.
Publicado: (2022)

Binding affinity-based intracellular drug detection enabled by a unimolecular cucurbit[7]uril-dye conjugate
por: Liu, Yanxi, et al.
Publicado: (2023)

Unlocking cellular barriers: silica nanoparticles and fullerenol conjugated cell-penetrating agents for enhanced intracellular drug delivery
por: Ravelo-Nieto, Eduardo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g63hpacgvr2c8or9mso2ofqsi5